prod:prod_dcx-login
Limit the spread. Improve the Outcome.
Every time a microorganism becomes resistant to an antibiotic, we lose another vital weapon in the war against infection. Newly resistant microorganisms are emerging—and spreading globally—every day. The result: antimicrobial resistance (AMR). In the very near future, we may be left without any drugs at all to fight serious, resistant infections.7
Antimicrobial resistance (AMR) leads to longer hospital stays, increased mortality, and higher medical costs.
AMR is one of the top 10 global public health threats facing humanity, with misuse and overuse of antimicrobials being the main drivers in the development of drug-resistant pathogens. In addition to death and disability, prolonged illness results in longer hospital stays and financial challenges for those impacted.1
Why AMR Matters:
2.8 Million
infections annually1
35,000
deaths annually in the U.S.2
4.6 Billion
in extra healthcare costs3
Relationship to Healthcare-Associated Infections (HAIs)4,5
HAIs are frequently caused by drug-resistant bacteria. HAIs can:
1 in 3
bacteria associated with HAIs are resistant to antibiotics4
4.5 Million
annual number of patients with at least one HAI5
1 in 15
number of patients on any given day with at least one HAI4
Everyone is at Risk6
Some, however, are high-risk and disproportionally impacted:
Patients undergoing cancer therapy
Patients with weakened immune systems
Patients undergoing dialysis
Patients undergoing complex surgery
Video
What is "The Antibiotic Apocalypse"?
The Antibiotic Apocalypse. It’s more dangerous than we thought.
Video
What is "The Antibiotic Apocalypse"?
The Antibiotic Apocalypse. It’s more dangerous than we thought.
How We Can Build Better Antibiotic Stewardship with the GeneXpert® System
With on-demand molecular diagnostics, today’s healthcare providers are able to quickly identify whether an infection is present and if it is drug-resistant, in minutes, rather than days. Cepheid’s GeneXpert® system helps those on the frontlines of resistance prevent the inappropriate use of antimicrobials and preserve our antibiotic weapons―now and in the future. For more information, download our antimicrobial stewardship brochure.
Video
Antibiotics "just-in-case" | Debbie Goff | TEDxColumbus
In a recent TEDx talk, Dr. Debbie Goff, a clinical pharmacist and global antimicrobial stewardship advocate, outlined a compelling case for shared accountability in the fight against drug-resistant organisms. With real-life examples of “just in case” antibiotic use, the case for stewardship is presented with impressive clarity and humanity.
Video
Carbapenemases
Dr. Tim Neal, Infection Control Doctor at Liverpool Clinical Laboratories, details how rapid molecular diagnostic solutions are critical to staying ahead of the emerging threat of carbapenemase-producing Enterobacteriaceae (CPE).
Read the related white paper
Video
Antibiotics "just-in-case" | Debbie Goff | TEDxColumbus
In a recent TEDx talk, Dr. Debbie Goff, a clinical pharmacist and global antimicrobial stewardship advocate, outlined a compelling case for shared accountability in the fight against drug-resistant organisms. With real-life examples of “just in case” antibiotic use, the case for stewardship is presented with impressive clarity and humanity.
Video
Carbapenemases
Dr. Tim Neal, Infection Control Doctor at Liverpool Clinical Laboratories, details how rapid molecular diagnostic solutions are critical to staying ahead of the emerging threat of carbapenemase-producing Enterobacteriaceae (CPE).
Read the related white paper
Related White Papers & Webinars
Antibiotic Stewardship in the Emergency Department
This webinar discusses the importance of diligent antimicrobial stewardship and accuracy of diagnostic tests for the detection of Group A Streptococcus pharyngitis. It provides commentary on the high confidence that molecular testing affords the antibiotic steward and how technology can reduce the practice of prescribing antibiotics "just-in-case" there is an infection, especially as testing moves closer to the patient.
More...
RDT+ASP: How New Rapid Diagnostics are Supercharging Antimicrobial Stewardship Programs
This webinar discusses data supporting the combination of rapid diagnostic tests (RDT) and antimicrobial stewardship programs (ASPs), reviews RDT systems, and provides guidance on how ASPs can implement and optimize the use of RDTs in virtually any healthcare setting.
More...
White Paper: Supporting CDC’s Four Core Actions to Fight Antimicrobial Resistance
CDC has declared the complex problem of AMR a serious threat today, which will result in potential catastrophic consequences with continued inaction. To combat AMR, the CDC has identified 4 core actions, all of which can be addressed through rapid molecular diagnostics:
More...
White Paper: Preventing "Nightmare Bacteria" from Becoming Nightmare Outbreaks
In early 2015, carbapenem-resistant Enterobacteriaceae (CRE) became a household term when a high-profile outbreak — including two deaths — at a California hospital were linked to contaminated medical scopes.
More...
Related Product Links
Xpert® Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP, and OXA-48 in 50 minutes
Xpert® SA Nasal Complete
Pre-surgical testing of S. aureus and MRSA in about 65 minutes
Xpert® Xpress CoV-2/Flu/RSV plus
Actionable rapid respiratory results to meet the challenges of co-circulating respiratory viruses
Xpert® CT/NG
90-minute detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
Xpert® Xpress Strep A
Delivers accurate and timely results that optimizes fast treatment decisions
1 Centers for Disease Control and Prevention: Antibiotic Resistance Threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
Accessed April 18, 2022.
2 World Health Organization: Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed April 18, 2022.
3 Centers for Disease Control and Prevention: CDC Study Shows National Healthcare Costs from AR Infections Exceed $4.6 Billion. https://www.cdc.gov/ncezid/what-we-do/partnership-in-
action/healthcare-costs-associated-with-ar-infections.html. Accessed April 18, 2022.
4 MedTech Europe. 2014. Healthcare-Associated Infections Brochure. Accessed Feb 2021. https://www.medtecheurope.org/resource-library/hai-brochure/
5 ECDC. 2018. Healthcare-Associated Infections - A Threat to Patient Safety in Europe. Accessed Feb 2021.
https://www.ecdc.europa.eu/en/publications-data/infographichealthcare-associated-infections-threat-patient-safety-europe
6 CDC. 2019. Antibiotic Resistance Threats in the United States 2019. Accessed Feb 2021. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
7 World Health Organization. “Antimicrobial resistance: global report on surveillance.” June, 2014.